Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

408 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
PERSIAN trial (NCT05717660): an ongoing randomized trial testing androgen deprivation therapy, apalutamide and stereotactic body radiotherapy. An alternative "triplet" for oligometastatic hormone sensitive prostate cancer patients.
Francolini G, Porreca A, Facchini G, Santini D, Bruni A, Simoni N, Trovò M, Osti MF, Fornarini G, Sisani M, Di Cataldo V, Detti B, Garlatti P, Bertini N, Serni S, Minervini A, Livi L. Francolini G, et al. Among authors: facchini g. Med Oncol. 2023 Dec 29;41(1):39. doi: 10.1007/s12032-023-02268-3. Med Oncol. 2023. PMID: 38157111 Clinical Trial.
Oncological Outcomes of Patients with High-Volume mCRPC: Results from a Longitudinal Real-Life Multicenter Cohort.
Ferriero M, Prata F, Anceschi U, Astore S, Bove AM, Brassetti A, Calabrò F, Chiellino S, De Nunzio C, Facchini G, Franzese E, Izzo M, Mastroianni R, Misuraca L, Naspro R, Papalia R, Pappalardo A, Tema G, Tuderti G, Turchi B, Tubaro A, Simone G. Ferriero M, et al. Among authors: facchini g. Cancers (Basel). 2023 Sep 29;15(19):4809. doi: 10.3390/cancers15194809. Cancers (Basel). 2023. PMID: 37835503 Free PMC article.
Real-World Impact of Upfront Cytoreductive Nephrectomy in Metastatic Non-Clear Cell Renal Cell Carcinoma Treated with First-Line Immunotherapy Combinations or Tyrosine Kinase Inhibitors (A Sub-Analysis from the ARON-1 Retrospective Study).
Fiala O, Buti S, Bamias A, Massari F, Pichler R, Maruzzo M, Grande E, De Giorgi U, Molina-Cerrillo J, Seront E, Calabrò F, Myint ZW, Facchini G, Kopp RM, Berardi R, Kucharz J, Vitale MG, Pinto A, Formisano L, Büttner T, Messina C, Monteiro FSM, Battelli N, Kanesvaran R, Büchler T, Kopecký J, Santini D, Giudice GC, Porta C, Santoni M. Fiala O, et al. Among authors: facchini g. Target Oncol. 2024 May 5. doi: 10.1007/s11523-024-01065-w. Online ahead of print. Target Oncol. 2024. PMID: 38704759
An Italian multicenter retrospective real-life analysis of patients with brain metastases from renal cell carcinoma: the BMRCC study.
Internò V, Massari F, Rudà R, Maiorano BA, Caffo O, Procopio G, Bracarda S, Atzori F, Passarelli A, Bersanelli M, Stellato M, Fornarini G, Galli L, Ortega C, Zanardi E, Incorvaia L, Facchini G, Giron Berrios JR, Ricotta R, Santoni M, Funaioli C, Trerotoli P, Porta C, Rizzo M. Internò V, et al. Among authors: facchini g. ESMO Open. 2023 Aug;8(4):101598. doi: 10.1016/j.esmoop.2023.101598. Epub 2023 Jul 17. ESMO Open. 2023. PMID: 37467658 Free PMC article.
Papillary Renal Cell Carcinoma: Outcomes for Patients Receiving First-line Immune-based Combinations or Tyrosine Kinase Inhibitors from the ARON-1 Study.
Massari F, Mollica V, Fiala O, De Giorgi U, Kucharz J, Vitale MG, Molina-Cerrillo J, Facchini G, Seront E, Lenci E, Bourlon MT, Carrozza F, Pichler R, Lolli C, Myint ZW, Kanesvaran R, Torniai M, Rescigno P, Gomez de Liaño A, Zakopoulou R, Buti S, Porta C, Grande E, Santoni M. Massari F, et al. Among authors: facchini g. Eur Urol Oncol. 2024 Apr 3:S2588-9311(24)00088-9. doi: 10.1016/j.euo.2024.03.011. Online ahead of print. Eur Urol Oncol. 2024. PMID: 38575409
Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer.
Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, Özgüroğlu M, Ye D, Feyerabend S, Protheroe A, De Porre P, Kheoh T, Park YC, Todd MB, Chi KN; LATITUDE Investigators. Fizazi K, et al. N Engl J Med. 2017 Jul 27;377(4):352-360. doi: 10.1056/NEJMoa1704174. Epub 2017 Jun 4. N Engl J Med. 2017. PMID: 28578607 Free article. Clinical Trial.
Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma.
Choueiri TK, Tomczak P, Park SH, Venugopal B, Ferguson T, Symeonides SN, Hajek J, Chang YH, Lee JL, Sarwar N, Haas NB, Gurney H, Sawrycki P, Mahave M, Gross-Goupil M, Zhang T, Burke JM, Doshi G, Melichar B, Kopyltsov E, Alva A, Oudard S, Topart D, Hammers H, Kitamura H, McDermott DF, Silva A, Winquist E, Cornell J, Elfiky A, Burgents JE, Perini RF, Powles T; KEYNOTE-564 Investigators. Choueiri TK, et al. N Engl J Med. 2024 Apr 18;390(15):1359-1371. doi: 10.1056/NEJMoa2312695. N Engl J Med. 2024. PMID: 38631003 Clinical Trial.
Case report: An ultrasound-based approach as an easy tool to evaluate hormone receptor-positive HER-2-negative breast cancer in advanced/metastatic settings: preliminary data of the Plus-ENDO study.
Montella L, Di Marino L, Marino MA, Riccio V, Del Gaudio N, Altucci L, Berretta M, Facchini G. Montella L, et al. Among authors: facchini g. Front Oncol. 2024 Apr 16;14:1295772. doi: 10.3389/fonc.2024.1295772. eCollection 2024. Front Oncol. 2024. PMID: 38690171 Free PMC article.
408 results